Robert W. Baird reissued their neutral rating on shares of BeiGene, Ltd. (NASDAQ:BGNE) in a research report released on Tuesday. The firm currently has a $83.00 price objective on the stock, up from their prior price objective of $58.00.
Several other equities analysts have also weighed in on BGNE. Ladenburg Thalmann Financial Services started coverage on shares of BeiGene in a report on Monday, August 7th. They issued a buy rating and a $81.00 price objective on the stock. Zacks Investment Research lowered shares of BeiGene from a buy rating to a hold rating in a report on Thursday, August 10th. Goldman Sachs Group, Inc. (The) restated a buy rating and issued a $86.00 price objective (up from $43.00) on shares of BeiGene in a report on Tuesday, August 15th. Maxim Group restated a buy rating and issued a $77.00 price objective on shares of BeiGene in a report on Monday, September 11th. Finally, Morgan Stanley restated an overweight rating and issued a $95.00 price objective (up from $87.00) on shares of BeiGene in a report on Friday, October 6th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and six have given a buy rating to the stock. The company has a consensus rating of Buy and an average price target of $96.67.
Shares of BeiGene (NASDAQ:BGNE) traded down $3.58 during midday trading on Tuesday, reaching $79.60. 628,400 shares of the company traded hands, compared to its average volume of 190,789. BeiGene has a fifty-two week low of $26.43 and a fifty-two week high of $118.95. The company has a current ratio of 8.38, a quick ratio of 8.38 and a debt-to-equity ratio of 0.57.
ILLEGAL ACTIVITY WARNING: “BeiGene’s (BGNE) “Neutral” Rating Reaffirmed at Robert W. Baird” was posted by Markets Daily and is the sole property of of Markets Daily. If you are accessing this story on another website, it was stolen and republished in violation of United States & international copyright & trademark legislation. The correct version of this story can be accessed at https://www.themarketsdaily.com/2017/11/15/beigenes-bgne-neutral-rating-reaffirmed-at-robert-w-baird.html.
A number of institutional investors and hedge funds have recently bought and sold shares of the business. California Public Employees Retirement System acquired a new stake in BeiGene in the third quarter worth $4,912,000. Perceptive Advisors LLC acquired a new stake in BeiGene in the third quarter worth $590,000. Orbimed Advisors LLC raised its holdings in BeiGene by 2.0% in the third quarter. Orbimed Advisors LLC now owns 1,313,788 shares of the company’s stock worth $135,925,000 after purchasing an additional 26,200 shares during the period. Janus Henderson Group PLC acquired a new stake in BeiGene in the third quarter worth $33,744,000. Finally, Jane Street Group LLC acquired a new stake in BeiGene in the third quarter worth $339,000. Institutional investors own 52.09% of the company’s stock.
BeiGene Company Profile
BeiGene, Ltd. is a clinical-stage biopharmaceutical company. The Company is focused in the discovery and development of molecularly targeted and immuno-oncology drugs for the treatment of cancer. The Company had used its cancer biology platform to develop four clinical-stage drug candidates, such as BGB-3111, BGB-A317, BGB-290 and BGB-283, as of December 31, 2016.
Receive News & Ratings for BeiGene Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BeiGene Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.